CAMP4 Therapeutics: Oppenheimer initiates coverage with outperform rating and $15 price target
CAMP•Oppenheimer initiated coverage of CAMP4 Therapeutics with an outperform rating and a $15 price target.
Related News
Westlake Vinnolit secures ISO 14067 product carbon footprint certification for PVC portfolio
WLK•
Hackett finds $1.94 trillion working capital opportunity at largest North American public companies
HCKT•
Nasdaq trade halt continues; reason not available at 09:42 a.m.
UCFIW•
PTC Inc.: Baird cuts to neutral rating
PTC•
AMEX halts trading; last at 5.57
SDEV•